As an innovative leader in the field of targeted radiopharmaceuticals, VitsGen recently announced that its Founder and President, Dr. Keene Wei, has been invited as an expert speaker at the 2nd TRP Target Selection & Drug Design Summit, to be held from February 24-26, 2026, in Boston, USA. The summit is currently the world's only professional conference focused on early-stage research and development of radiopharmaceutical therapies (RLT), bringing together top experts and innovators from academia and industry.

At the conference, Dr. Keene Wei will deliver the opening keynote address for the session on "Intelligent Design of Radiopharmaceuticals," titled "Design of Peptide-Based Radiopharmaceutical Conjugates: Achieving Ideal Targeting and Dosimetric Characteristics." Drawing upon VitsGen's systematic R&D practices in targeted radionuclide therapy, his presentation will delve into how next-generation multi-targeting peptide (MAP) strategies can address core challenges in traditional radiopharmaceuticals related to biodistribution, tumor selectivity, and safety margins. He will also explore how a dosimetry-driven approach can precisely bridge the gap from molecular design to clinical benefit.

Dr. Keene Wei commented, "The TRP Summit represents a highly influential, high-level platform for exchange in the global targeted radiopharmaceutical field. I look forward to engaging in in-depth discussions and exploring potential collaborations with colleagues from around the world—whether on the systematic consideration of target selection or the practical pathways of using dosimetry to inversely drive drug design."

VitsGen is dedicated to building a globally competitive pipeline of radiotherapeutic and diagnostic products, anchored by proprietary targeting moiety design and advanced delivery technologies. Dr. Keene Wei's invitation to deliver the opening address not only underscores the international community's high regard for his academic influence and technical vision but also further solidifies VitsGen's industry standing and thought leadership in the early-stage innovation and development of radiopharmaceuticals.